Secondary Logo

Journal Logo

January 2, 2006 - Volume 20 - Issue 1
pp: 1-142


Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients

Vora, Samir; Marcelin, Anne-Geneviève; Günthard, Huldrych F; More

AIDS. 20(1):35-40, January 2, 2006.

Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya

Wools-Kaloustian, Kara; Kimaiyo, Silvester; Diero, Lameck; More

AIDS. 20(1):41-48, January 2, 2006.

Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease

Merchante, Nicolás; Girón-González, José A; González-Serrano, Mercedes; More

AIDS. 20(1):49-57, January 2, 2006.

Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy

Suy, Anna; Martínez, Esteban; Coll, Oriol; More

AIDS. 20(1):59-66, January 2, 2006.


Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda

Bunnell, Rebecca; Ekwaru, John Paul; Solberg, Peter; More

AIDS. 20(1):85-92, January 2, 2006.


Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: differences before and after HAART

Lumbreras, Blanca; Jarrín, Inmaculada; del Amo, Julia; More

AIDS. 20(1):111-116, January 2, 2006.


Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results

Manosuthi, Weerawat; Kiertiburanakul, Sasisopin; Sungkanuparph, Somnuek; More

AIDS. 20(1):131-132, January 2, 2006.